The woods are lovely, dark and deep, But I have promises to keep, And miles to go before I sleep, And miles to go before I sleep.
T ranscatheter aortic valve implantation (TAVI) is arguably the most exciting recent advance in interventional cardiology and cardiovascular surgery. Indeed, this innovation in cardiovascular therapeutics has been a wellcoordinated collaborative effort by both physicians and surgeons alike. [2] [3] [4] [5] [6] [7] [8] The result of this approach has enabled the rapid acceptance of TAVI in Europe. This new method has met the need for a less-invasive solution to treat severe aortic stenosis in the high-risk elderly population, in whom few options were available. This has been the main impetus for the rapid dissemination of the technique despite limited comparative data in large populations, although smaller studies have been encouraging. 5, 6, 8 
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Since the first TAVI was performed in a patient in 2002, 2 valve engineering and delivery iterations have been developed to improve the clinical applicability of the new therapeutic modality, which has led to a rich and very promising new concept in medicine. Thus, we now have 2 different TAVI systems, Edwards SAPIEN (Edwards Life Sciences, Irvine, Calif) and CoreValve (Medtronic Inc, Minneapolis, Minn), that are clinically available internationally except in the United States. Furthermore, several new prostheses with original designs are in various stages of clinical investigation.
After the initial clinical experience and alterations of both prostheses and the delivery systems, the technique of TAVI has become fairly standardized, with predictable outcomes. The collaborative work of both engineers and interventionalists deserves credit for making this procedure a widely applicable one. In this issue of Circulation, Thomas et al 9 document the impact of the collective effort by stating that "[t]wenty-three of the 32 sites (72%) had no prior experience with the Edwards SAPIEN valve, and these centers enrolled 578 patients (56%) in the registry." The combination of the standardized technique and the systematic utilization of the structured program of training and proctorship was the basis for the successful program even at sites that started to contribute to the registry with no prior experience. This report provides important insight into the outcomes of TAVI, but it is limited by its mostly retrospective collection of data, self-reporting, and lack of a comparison group. The randomized, controlled Placement of AoRTic TraNscathetER Valve (PARTNER) trial will further elucidate the safety and efficacy of TAVI in relation to medical management or surgery. 10 For a new aortic valve prosthesis to be widely accepted into clinical practice, it must meet 4 criteria. 11 These include, (1) ease of implantation, (2) safety, (3) large effective orifice area, and (4) structural durability. We expect that similar-risk patients receiving valvular prostheses via the transcatheter route should have a long-term survival equivalent to that seen with the currently available surgically placed devices and should have a superior outcome compared with medically treated patients on the basis of the Transcatheter EndoVascular Implantation of Valves (REVIVAL) trial data. 5, 6 In addition to survival, improvement in quality of life is an important component of the outcome. 5 Better quality of life may be as valuable as the addition of months to years to the life span, particularly in the elderly aortic stenosis patient with multiple comorbidities.
The procedural success, variably defined as the patient leaving the procedure room with an implanted prosthesis without a major complication, was 82% in the initial experience of the Vancouver group and 87% in the Transcatheter EndoVascular Implantation of Valves feasibility trial. 3, 5, 12 Webb et al 13 demonstrated that the success rate rises substantially with increasing experience. In the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry, the success rate was 93.8%. The high success rate of this multicenter experience was comparable to that of other contemporary series demonstrating the importance of training, increasing ease of insertion, and experience. 12 Safety of the TAVI procedure continues to be an important consideration in the evaluation of the data. The potential for serious, life-threatening complications exists at every step of the TAVI procedure. For example, in the early phase of the Transcatheter EndoVascular Implantation of Valves feasibility trial, there was a high rate of iliofemoral access-site vascular complications and accompanying high mortality rates. This alerted the investigators, who instituted a series of measures that reduced the frequency of these events and the overall mortality. In the SOURCE registry, 49 (10.6%) of the 463 patients had major vascular complications out of a total of 106 access complications (22.9%). It is gratifying to see that even though the rate of such complications was still high, they had no impact on 30-day mortality. This finding suggests that the teams who were performing the procedure were well prepared to manage the potentially life-threatening vascularaccess problems. Major vascular complications were less frequent in the transapical-approach group (nϭ14, 2.4%; nϭ27, 4.7%); however, when vascular complications occurred in the transapical group, the mortality was very high, although the nature of the vascular complications was not defined. The causes of this high mortality rate merit further study and corrective action, because this has not been reported previously.
Although the overall results of TAVI in this trial are good, as the authors stated, it is impossible to compare the 2 groups because of the differences in patient characteristics and the fact that patients with poor access were enrolled in the transapical group. Peripheral Vascular Disease is included in the Society of Thoracic Surgeons aortic valve risk score that predicts increased mortality, as reported previously. 5, 7, 14 Despite these baseline differences, the large data set provides some insights about the safety of the 2 approaches and their particular strengths. Clearly, the transapical route is preferred in those patients whose iliofemoral arteries and aorta, whether due to atheroma or calcium, are unsuitable for cannulation with large sheaths. Whether the transapical approach may offer certain advantages over the transfemoral approach in equal-risk patients has been debated. The main reason for this is that in the transfemoral approach, the new valve device is pushed by the delivery catheter carrying the valve-balloon system around the aortic arch to the ascending aorta and into the native valve, which may expose the patient to the risk of cerebral embolism. Furthermore, it was deduced that the transapical approach would be associated with a lower risk of stroke, because manipulation of the catheter is mostly confined to the left ventricle plus the aortic root. Indeed, early reports, including the US transapical feasibility trial, showed a very low risk of stroke. 5, 8 In the current SOURCE study, although the characteristics of the transapical and transfemoral patients were dissimilar, there was no suggestion of higher stroke rates with the transfemoral approach (2.4% transfemoral versus 2.6% transapical approach). This is in congruence with data showing similar strokes rates in transapical and transfemoral groups in another series. 12 Obviously, it can be argued that subtle neurological deficits might have been missed in this largely retrospective registry owing to the lack of systematic pre-and post-TAVI neurological examinations. Despite this possibility, the transfemoral approach does not appear to be associated with a higher risk of clinically relevant cerebrovascular events. Moreover, emerging emboli prevention devices will likely provide new methods to protect the brain during TAVI. Furthermore, it was believed that the short distance between the apex and the aortic valve would allow for more precise and safer placement of the prosthesis, but with the further development of the transfemoral approach, data from Europe suggest that placement of the valve via a transfemoral approach is quite accurate, with fewer than 0.7% of patients experiencing valve embolization or coronary obstruction.
Renal insufficiency is an important predictor of adverse outcome in any cardiovascular intervention. In the SOURCE registry, 7.1% of transapical and 1.3% of transfemoral patients developed renal failure that required dialysis. At baseline, more patients in the transapical group had renal dysfunction and peripheral vascular disease, which explains in part the difference between the 2 groups. Meticulous attention should be paid to the potential causes of renal failure, such as intraprocedural hypotension, contrast load, and concomitant medications. Whether there is a potential difference between the techniques with equivalent patients will require further study.
The report by Thomas et al 9 provides insight into the safety of the TAVI procedure but has limited data on the performance of the prosthesis. Previous studies have documented a dramatic reduction in the left ventricle-aortic gradient and a marked increase in the valve area. 5, 8, 12, 15 On the basis of postoperative echocardiograms, the effective orifice area of the Edwards SAPIEN prosthesis is as good as, if not better than, that of valves placed in open surgery. The excellent hemodynamic performance of the transcatheter prosthesis is clouded slightly by the frequent occurrence of paravalvular aortic regurgitation. In the SOURCE registry, fewer than 2% of the patients had Ͼ2ϩ aortic regurgitation after valve implantation. This number should be interpreted cautiously, because the echocardiography data in this registry were not arbitrated by an independent core laboratory. Assessment of the severity of paravalvular aortic regurgitation is particularly challenging and open to inconsistencies. Therefore, interpretation of the data on aortic regurgitation in this and other reports is difficult. Nevertheless, Յ2ϩ aortic regurgitation, which is more frequent, appears to be well tolerated without heart failure or hemolysis, although the long-term consequence remains unclear.
As noted previously, the mortality rate with TAVI was higher in earlier reports, at 7.2% for the transfemoral arm and 17% for the transapical arm of the US Transcatheter Endo-Vascular Implantation of Valves trial. 5 Similar to the procedural success, the mortality rate has also improved with experience. The SOURCE registry, which has the largest patient population reported to date, includes 463 transfemoral and 575 transapical patients. Thirty-day mortality of the entire cohort was 8.5%, with respective mortality rates of 6.3% and 10.3% in the transfemoral and transapical groups. It is interesting to note that in patients undergoing transfemoral TAVI, the risk of mortality was comparable for patients with low or high EuroSCOREs (EUROpean System for Cardiac Operative Risk Evaluation) (5.4% versus 6.7%), which highlights the fact that transfemoral TAVI can be accomplished in patients with severe comorbidities without increasing the procedural risk. This is in contrast to the transapical TAVI, for which the 30-day morality rates were 6.6% and 11.9%, respectively, in patients with a EuroSCORE Ͻ20 and Ն20.
The logistics EuroSCORE was developed 15 years ago from 19 000 consecutive patients, of whom only 17% had aortic valve replacement. 16 Moreover, only a small minority of these patients had high-risk characteristics similar to the TAVI patients in the SOURCE registry. It is well documented that the logistic EuroSCORE overpredicts the risk of opera- The Placement of AoRTic TraNscathetER Valve trial will demonstrate conclusively the value of TAVI compared with medical therapy and conventional aortic valve replacement, but not in patients who are not at high risk. Trials aimed at exploring the role of TAVI in lower-risk patients are in the planning stages. Only after such trials have been conducted will we learn whether the results of TAVI are comparable to those of contemporary surgical aortic valve replacement in lower-risk patients.
The current results outlined in this large registry are encouraging as an initial experience. Nevertheless, the serious complications, such as coronary occlusion, mal-position of the device, and aortic regurgitation, will need to be reduced and mortality risk should match that of the low-risk surgical aortic valve replacement if TAVI is to be applied to larger population of aortic stenosis patients. In high-risk patients, TAVI meets the criteria of ease of insertion, safety, and excellent orifice area, but its long-term durability remains to be determined.
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